As the global biopharmaceutical industry continues to develop increasingly complex therapies, the demand for advanced analytical testing has never been greater. Drug developers are under growing pressure to demonstrate product safety, quality, and consistency from the earliest stages of research through commercial manufacturing. Technologies capable of delivering detailed protein analysis are becoming essential for meeting strict regulatory requirements while accelerating the development of innovative medicines. Strengthening its position in this rapidly evolving market, French quality control specialist Clean Cells has expanded its scientific capabilities through the acquisition of mass spectrometry expert Anaquant.
Clean Cells has announced the acquisition of French bioanalysis company Anaquant, a specialist in protein quantification and identification using mass spectrometry technology.
The acquisition enhances Clean Cells’ analytical capabilities while creating a more comprehensive service portfolio for biopharmaceutical companies developing advanced therapies.
Expanding Scientific Expertise
Founded in 2020 as a subsidiary of Clean Biologics, Clean Cells provides quality control and biological safety testing for biopharmaceutical products to support regulatory compliance throughout the drug development process.
The company also produces cell banks and Good Manufacturing Practice grade virus seed stocks while offering secure storage solutions and customised analytical method development.
Its services are designed to help biotechnology and pharmaceutical companies maintain product quality while meeting increasingly demanding international regulatory standards.
With the addition of Anaquant, Clean Cells significantly expands its expertise in protein characterisation, an area that plays a critical role in ensuring the safety and effectiveness of biological medicines.
Strengthening Protein Characterisation
Anaquant is a contract research organisation specialising in protein identification and quantification through advanced mass spectrometry.
Its analytical platform enables biotechnology companies to generate highly detailed protein data during the early phases of drug development, supporting future regulatory submissions and product optimisation.
As part of the transaction, Clean Cells has acquired Anaquant’s brand, intellectual property, proprietary analytical platform, specialised equipment, and existing customer relationships.
The integration of these capabilities enables Clean Cells to offer more advanced analytical services while providing clients with deeper scientific insight throughout product development.
Enhancing Regulatory Readiness
One of the most valuable additions included in the acquisition is Anaquant’s patented ReadyBeads technology.
The product serves as a reference standard for analysing Host Cell Proteins, residual impurities that remain after biological manufacturing processes and require increasingly sophisticated analytical evaluation.
Accurate measurement of these proteins is essential for demonstrating product purity, safety, and manufacturing consistency before regulatory approval.
By integrating ReadyBeads into its service portfolio, Clean Cells will provide clients with stronger analytical datasets that improve confidence during regulatory submissions and support successful product approvals.
Creating an End to End Analytical Platform
The acquisition allows Clean Cells to build a comprehensive analytical offering that supports customers throughout every stage of biopharmaceutical development.
From early research and analytical method development to Good Manufacturing Practice compliant release testing, the combined platform delivers continuous scientific support across the entire product lifecycle.
This integrated approach simplifies quality control processes while reducing the need for multiple external service providers.
The expanded platform is expected to improve efficiency for biotechnology companies developing complex biological therapies while ensuring consistent analytical standards.
Supporting the Future of Biopharmaceutical Innovation
As biological medicines continue to become more sophisticated, regulatory authorities increasingly require deeper scientific understanding of product composition and manufacturing quality.
Advanced protein characterisation technologies such as mass spectrometry are therefore becoming indispensable tools within modern pharmaceutical development.
With the acquisition of Anaquant, Clean Cells is strengthening its position as a comprehensive analytical partner for biotechnology companies worldwide. By combining regulatory expertise, biological safety testing, advanced protein analysis, and specialised reference technologies within a unified platform, the company is expanding its ability to support customers from early research through commercial manufacturing, helping accelerate the delivery of safe and effective biopharmaceutical products to patients around the world.